Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Idera anticipates using the net proceeds from the offering to fund its planned Phase 1/2 clinical trials of IMO-8400 intended to evaluate its use in certain genetically defined forms of B-cell lymphomas, to fund its planned Phase 1 clinical trial of IMO-9200 and for working capital and other general corporate purposes.
The securities described above are being offered by the Company pursuant
to a shelf registration statement previously filed with and declared
effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Idera's technology platform involves creating novel synthetic RNA- and DNA-based compounds to modulate immune responses. Idera has applied this platform to develop proprietary Toll-like receptor (TLR) antagonists as immunomodulatory drug candidates. Toll-like receptor antagonists block the overactivation of immune factors which can cause a range of pathological effects. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma. More information on Idera is available at iderapharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding the
Company’s strategy, future operations, collaborations, intellectual
property, cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”
“potential,” “likely,” “projects,” “continue,” “will,” and “would” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking statements
and you should not place undue reliance on the Company’s forward-looking
statements. There are a number of important factors that could cause
Idera’s actual results to differ materially from those indicated or
implied by its forward-looking statements. Factors that may cause such a
difference include: whether Idera’s cash resources will be sufficient to
fund its continuing operations and the further development of the
Company’s programs; whether results obtained in early research,
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical studies; whether
products based on Idera’s technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the
Source:
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com